The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus;Rola białka PD-1 w patogenezie chorób autoimmunizacyjnych, ze szczególnym uwzglȩdnieniem reumatoidalnego zapalenia stawów oraz tocznia rumieniowatego układowego

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 69, Issue , 2015, Pages 534-542

  Siwiec, Anna ^a   Majdan, Maria ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Autoimmune diseases; Genetics; Immunology; Pathogenesis; PD 1 protein; Polymorphism; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

CYTOKINE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ARTHRITIS, RHEUMATOID; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; METABOLISM;

ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; POLYMORPHISM, GENETIC; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84973434453     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1150784     Document Type: Review

References (48)

1. Adhami E.: Calculating the etiology of systemic lupus erythematosus. Med. Hypotheses, 2004; 62: 237-246
2. Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., Honjo T.: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol., 1996; 8: 765-772
3. Bennett F., Luxenberg D., Ling V., Wang I.M., Marquette K., Lowe D., Khan N., Veldman G., Jacobs K.A., Valge-Archer V.E., Collins M., Carreno B.M.: Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J. Immunol., 2003; 170: 711-718
4. Bertsias G.K., Nakou M., Choulaki C., Raptopoulou A., Papadimitraki E., Goulielmos G., Kritikos H., Sidiropoulos P., Tzardi M., Kardassis D., Mamalaki C., Boumpas D.T.: Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum., 2009; 60: 207-218
5. Bijl M., Horst G., Limburg P.C., Kallenberg C.G.: Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann. Rheum. Dis., 2001; 60: 523-526
6. Bolstad A.I., Eiken H.G., Rosenlund B., Alarcón-Riquelme M.E., Jonsson R.: Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum., 2003; 48: 174-185
7. Ding H., Wu X., Wu J., Yagita H., He Y., Zhang J., Ren J., Gao W.: Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin. Immunol., 2006; 118: 258-267
8. Ferreiros-Vidal I., Gomez-Reino J.J., Barros F., Carracedo A., Carreira P., Gonzalez-Escribano F., Liz M., Martin J., Ordi J., Vicario J.L., Gonzalez A.: Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. Arthritis Rheum., 2004; 50: 2590-2597
9. Fife B.T., Pauken K.E.: The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. NY Acad. Sci., 2011; 1217: 45-59
10. Finger L.R., Pu J., Wasserman R., Vibhakar R., Louie E., Hardy R.R., Burrows P.D., Billips L.G.: The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene, 1997; 197: 177-187
11. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., Honjo T.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 2000; 192: 1027-1034
12. Gianchecchi E., Delfino D.V., Fierabracci A.: Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev., 2013; 12: 1091-1100
13. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., Dustin M.L.: The immunological synapse: a molecular machine controling T cel activation. Science, 1999; 285: 221-227
14. Hatachi S., Iwai Y., Kawano S., Morinobu S., Kobayashi M., Koshiba M., Saura R., Kurosaka M., Honjo T., Kumagai S.: CD4+PD-1+T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol., 2003; 30: 1410-1419
15. Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G.J., Minato N., Honjo T.: Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett., 2002; 84: 57-62
16. Ishida Y., Agata Y., Shibahara K., Honjo T.,: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J., 1992; 11: 3887-3895
17. Iwamoto T., Ikari K., Inoue E., Toyama Y., Hara M., Yamanaka H., Tomatsu T., Momohara S., Kamatani N.: Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population. J. Hum. Genet., 2007; 52: 557-560
18. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M.: Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol., 1997; 84: 223-243
19. Kasagi S., Kawano S., Kumagai S.: PD-1 and autoimmunity. Crit. Rev. Immunol., 2011; 31: 265-295
20. + T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J. Immunol., 2010; 184: 2337-2347
21. Kobayashi M., Kawano S., Hatachi S., Kurimoto C., Okazaki T., Iwai Y., Honjo T., Tanaka Y., Minato N., Komori T., Maeda S., Kumagai S.: Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome. J. Rheumatol., 2005; 32: 2156-2163
22. Kong E.K., Prokunina-Olsson L., Wong W.H., Lau C.S., Chan T.M., Alarcón-Riquelme M., Lau Y.L.: A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum., 2005; 52: 1058-1062
23. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S, Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H.: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell, 1995; 80: 707-718
24. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., Greenfield E.A., Bourque K., Boussiotis V.A., Carter L.L., Carreno B.M. i wsp.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol., 2001; 2: 261-268
25. Lee S.H., Lee Y.A., Woo D.H., Song R., Park E.K., Ryu M.H., Kim Y.H., Kim K.S, Hong S.J., Yoo M.C., Yang H.I.: Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res. Ther., 2006; 8: R163
26. Lin S.C., Yen J.H., Tsai J.J., Tsai W.C., Ou T.T, Liu H.W., Chen C.J.: Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum., 2004; 50: 770-775
27. Long E.O.: Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol., 1999; 17: 875-904
28. Miyazaki Y., Tsumiyama K., Yamane T., Ito M., Shiozawa S.: Expansion of PD-1-positive effector CD4 T cells in an experimental model of SLE: contribution to the self-organized criticality theory. Kobe J. Med. Sci., 2013; 59: E64-E71
29. Mostowska M., Wudarski M., Chwalińska-Sadowska H., Jagodziński P.P.: The programmed cell death 1 gene 7209 C>T polymorphism is associated with the risk of systemic lupus erythematosus in the Polish population. Clin. Exp. Rheumatol., 2008; 26: 457-460
30. Nielsen C., Hansen D., Husby S., Jacobsen B.B., Lillevang S.T.: Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens, 2003; 62: 492-497
31. Nishimura H., Nose M., Hiai H., Minato N., Honjo T.: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 1999; 11: 141-151
32. Okazaki T., Honjo T.: PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol., 2007; 19: 813-824
33. Okazaki T., Honjo T.: The PD-1 - PD-L pathway in immunological tolerance. Trends Immunol., 2006; 27: 195-201
34. Park Y.B., Lee S.K., Kim D.S., Lee J., Lee C.H., Song C.H.: Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol., 1998; 16: 283-288
35. Paterson D.J., Jefferies W.A., Green J.R., Brandon M.R., Corthesy P., Puklavec M., Williams A.F.: Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD positive T blasts. Mol. Immunol., 1987; 24: 1281-1290
36. Prokunina L., Castillejo-López C., Oberg F., Gunnarsson I., Berg L., Magnusson V., Brookes A.J., Tentler D., Kristjansdóttir H., Gröndal G., Bolstad A.I., Svenungsson E., Lundberg I., Sturfelt G., Jönssen A. i wsp.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet., 2002; 32: 666-669
37. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., Prince J., Alfredsson L., Klareskog L., Alarcón-Riquelme M.: Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum., 2004; 50: 1770-1773
38. Raptopoulou A.P., Bertsias G., Makrygiannakis D., Verginis P., Kritikos I., Tzardi M., Klareskog L., Catrina A.I., Sidiropoulos P., Boumpas D.T.: The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum., 2010; 62: 1870-1880
39. Shinohara T., Taniwaki M., Ishida Y., Kawaichi M., Honjo T.: Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics, 1994; 23: 704-706
40. Sidorenko S.P., Clark E.A.: The dual-function CD150 receptor subfamily: the viral attraction. Nat. Immunol., 2003; 4: 19-24
41. Sinha A.A. Lopez M.T., McDevitt H.O.: Autoimmune diseases: the failure of self tolerance. Science, 1990; 248: 1380-1388
42. Tahoori M.T., Pourfathollah A.A., Akhlaghi M., Daneshmandi S., Nicknam M.H., Soleimanifar N.: Association of programmed cell death-1 (PDCD-1) gene polymorphisms with rheumatoid arthritis in Iranian patients. Clin. Exp. Rheumatol., 2011; 29: 763-767
43. Tokuhiro S., Yamada R., Chang X., Suzuki A., Kochi Y., Sawada T., Suzuki M., Nagasaki M., Ohtsuki M., Ono M., Furukawa H., Nagashima M., Yoshino S., Mabuchi A., Sekine A. i wsp.: An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat. Genet., 2003; 35: 341-348
44. Vibhakar R., Juan G., Traganos F., Darzynkiewicz Z., Finger L.R.: Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp. Cell Res., 1997; 232: 25-28
45. Wan B., Nie H., Liu A., Feng G., He D., Xu R., Zhang Q., Dong C., Zhang J.Z.: Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol., 2006; 177: 8844-8850
46. Wang G., Hu P., Yang J., Shen G., Wu X.: The effects of PDL-Ig on collagen-induced arthritis. Rheumatol. Int., 2011; 31: 513-519
47. Wang J., Shan Y., Jiang Z., Feng J., Li C., Ma L., Jiang Y.: High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin. Exp. Immunol., 2013; 174: 212-220
48. Wang S.C., Chen Y.J., Ou T.T., Wu C.C., Tsai W.C, Liu H.W., Yen J.H.: Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J. Clin. Immunol., 2006; 26: 506-511